182344-56-5

Basic information

• Product Name: 2-Chloro-4-fluorobenzothiazole
• Synonyms: IFLAB-BB F1910-0007;2-CHLORO-4-FLUOROBENZOTHIAZOLE;2-CHLORO-4-FLUORO-1,3-BENZOTHIAZOLE;Benzothiazole, 2-chloro-4-fluoro- (9CI);2-Chloro-4-fluorobenzo[d]thiazole
• CAS NO: 182344-56-5
• Molecular Formula: C7H3ClFNS
• Molecular Weight: 187.62
• Product Categories: BENZOTHIAZOLE
• Mol File: 182344-56-5.mol

Chemical Properties

• Boiling Point: 253 °C at 760 mmHg
• Flash Point: 106.8 °C
• Appearance: /
• Density: 1.532 g/cm³
• Vapor Pressure: 0.036mmHg at 25°C
• Refractive Index: 1.637
• CAS DataBase Reference: 2-Chloro-4-fluorobenzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-fluorobenzothiazole(182344-56-5)
• EPA Substance Registry System: 2-Chloro-4-fluorobenzothiazole(182344-56-5)

Safety Data

• Hazardous Substances Data: 182344-56-5(Hazardous Substances Data)

Usage

Chemical Properties

Pale yellow solid

InChI:InChI=1/C7H2ClF2NS/c8-7-11-6-4(10)1-3(9)2-5(6)12-7/h1-2H

Upstream product

• 154327-24-9 4-fluoro-2-mercaptobenzothiazole 
• 5509-65-9 2,6-difluoroaniline 

Downstream Products

• 753441-57-5 (4-fluoro-1,3-benzothiazol-2-yl)hydrazine 

Relevant articles and documents

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

Alpha-dystroglycan (α-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of α-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of α-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of α-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of α-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of α-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of α-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

New herbicidal fluorobenzothiazolyloxyacetamides

Novel herbicidal fluorobenzothiazolyloxyacetamides of the formula STR1 in which R1 represents hydrogen or an optionally substituted radical from the group consisting of alkyl, alkenyl, alkinyl and aralkyl, R2 represents an optionally